N4 Pharma PLC Nuvec® research update (6848I)
28 November 2018 - 6:00PM
UK Regulatory
TIDMN4P
RNS Number : 6848I
N4 Pharma PLC
28 November 2018
28 November 2018
N4 Pharma Plc
("N4 Pharma" or the "Company")
Nuvec(R) research update and timings for further work
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing a novel delivery system for vaccines and cancer
treatments, today announces a further update on the latest key
research findings for the Company's Nuvec(R) delivery system.
As announced on 29 October 2018, research undertaken to that
date indicated that the Company's Nuvec(R) particles themselves
have demonstrated a clear adjuvant effect to help deliver a level
of immune response for both messenger RNA ("mRNA") and plasmid DNA
("pDNA") encoded with the standard test antigen Ovalbumin
("OVA").
The Company has now undertaken further analysis of its pDNA OVA
findings and demonstrated that the immune response observed was
sufficient to have produced strong levels of antibodies specific
for OVA. A strong level of antibody production is essential for a
vaccine to deliver immunity. The levels of antibodies produced were
greater than those of in vivo-jetPEI(R), an industry standard used
to deliver pDNA-OVA in pre clinical studies. Furthermore, assessing
the detailed classes of antibodies produced has shown that Nuvec(R)
delivers a strong robust level of the specific antibodies needed
for effective oncology and virology vaccines.
The Company has also now manufactured one new large batch of
particles for its EUNCL and Adelaide research work and will be
shipping particles from this batch to the relevant parties shortly.
The research for these programs will now commence fully in January
2019. EUNCL is expected to deliver results towards the end of Q3
2019. The first part of the Adelaide work will take 4 weeks and
start in the new year, with results expected during Q1 2019.
Nigel Theobald, CEO of N4 Pharma commented:
"These results are once again another positive step forward for
our Nuvec(R) delivery platform. The data now shows Nuvec(R) is
capable of producing specific and relevant strong levels of
antibodies required for the development of vaccines and cancer
treatments.
"We will continue to provide updates as we add to our already
encouraging data package to aid our commercial collaboaration
discussions. The production of a robust data package using the test
antigen Ovalbumin provides compelling evidence of the potential for
Nuvec(R) to be an effective delivery system for a potential
partner's specific DNA or RNA antigen. "
Enquiries:
N4 Pharma Plc
Nigel Theobald, CEO Via Alma PR
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Asha Chotai
Alma PR
Josh Royston Tel: +44(0)778 090 1979
Robyn Fisher Tel: +44(0)754 070 6191
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for vaccines and cancer treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
Nuvec(R) has shown to be capable of loading and delivering mRNA
and pDNA into cells to the required level needed to generate an
immune response capable of strong antibody production. Further work
will be undertaken for the direct loading and delivery of peptides
and proteins using Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for vaccines and cancer treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
Glossary:
Adjuvant: An immunological agent that is used in vaccines to
help boost the immune response to produce more antibodies for
longer lasting immunity.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESDDLFLVFFLFBK
(END) Dow Jones Newswires
November 28, 2018 02:00 ET (07:00 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Apr 2024 to May 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
From May 2023 to May 2024